Skip to main content
$20.52 $0.54 (2.7%)

04:00 PM EDT on 07/30/21

Myovant Sciences Ltd. (NYSE:MYOV)

CAPS Rating: 2 out of 5

Current Price $20.52 Mkt Cap $1.8B
Open $19.98 P/E Ratio 0.00
Prev. Close $20.52 Div. (Yield) $0.00 (0.0%)
Daily Range $19.75 - $20.59 Volume 534,718
52-Wk Range $13.42 - $30.90 Avg. Daily Vol. 795,816

Caps

How do you think NYSE:MYOV will perform against the market?

Add Stock to CAPS Watchlist

All Players

20 Outperform
3 Underperform
 

All-Star Players

2 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:MYOV Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mdriver78 (74.60)
Submitted December 09, 2020

Biotech’s products, harnessing the latest science and designed and engineered to heal and improve the quality and length of human life, enjoy inexhaustible demand.And as that science advances so do the cures, and the profit opportunities for biotech… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NYSE:MYOV VS S&P 500 (SPY)

NYSE:MYOV Summary

Fools bullish on NYSE:MYOV are also bullish on:

Fools bearish on NYSE:MYOV are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MYOV.

Recs

1
Member Avatar mdriver78 (74.60) Submitted: 12/9/2020 11:18:10 AM : Outperform Start Price: $24.26 NYSE:MYOV Score: -34.14

Biotech’s products, harnessing the latest science and designed and engineered to heal and improve the quality and length of human life, enjoy inexhaustible demand.

And as that science advances so do the cures, and the profit opportunities for biotech investors. We’re on the threshold of finding cures for the most debilitating diseases like cancer, Alzheimer’s and heart disease

These new cures bring the potential for dizzying gains.

You see, there are numerous discrete events that can have earth-shattering impacts on a company's share price.

There are buyouts and mergers just as with any other type of business, but there are also lucrative partnerships that are signed to develop a promising new therapeutic. Plus, the biotech calendar is rich in events like clinical trials initiated or completed, data releases from these trials and the FDA's regulatory decisions.

These regulatory decisions come with dates... and the FDA is very good at meeting its decision schedule. Few sectors can give you such defined events. They often make perfect trading plays.

And the market has never been more bullish on biotech, taking shares to record highs this month.

The wealth potential isn’t lost on people in the finance sector. One example is Vivek Ramaswamy, who emerged at a young age from the world of finance when he left an investment management company to found his own biotech empire.

The wunderkind founded Roivant Sciences, which went public in 2015. Roivant went on to start or spin off more than a dozen subsidiaries. And Ramaswamy’s biotech empire spans companies specializing in everything from companies looking to cure neurodegenerative diseases to gene therapy and cardiovascular diseases.

One of the companies he founded, Myovant Sciences (NYSE: MYOV), is dedicated to women’s health and prostate cancer.

The company’s pipeline of drugs in development include treatments for female infertility, uterine fibroids, endometriosis and prostate cancer.

Because there’s a huge opportunity in Myovant right around the corner!

The company has taken its prostate cancer drug, relugolix, through several expensive clinical trials.

The drug is so promising, the FDA has granted it priority review. The regulatory agency has set a decision date for Dec. 20, 2020. On that date, the FDA will issue its decision on whether or not Myovant can market relugolix for the treatment of prostate cancer.

Myovant’s clinical trials for relugolix reveals that the odds of approval are very good.

Recs

0
Member Avatar ebadger33 (< 20) Submitted: 5/7/2020 9:40:57 PM : Outperform Start Price: $12.88 NYSE:MYOV Score: +8.70

this stock has seen huge insider interest in buying $11MM. Also moving over the 55 Moving Avg for quite some time. I believe it will keep moving for some time.

Recs

0
Member Avatar QueenAnneFool (31.81) Submitted: 2/7/2019 1:38:36 PM : Outperform Start Price: $18.55 NYSE:MYOV Score: -52.13

Smart leadership in a large addressable market.

Leaderboard

Find the members with the highest scoring picks in MYOV.

Score Leader

mrkher

mrkher (< 20) Score: +206.23

The Score Leader is the player with the highest score across all their picks in MYOV.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
mrkher < 20 11/12/2019 Outperform 5Y $5.89 +248.39% +42.16% +206.23 0 Comment
Lienbuster 96.20 6/17/2019 Outperform 5Y $8.95 +129.27% +51.31% +77.96 0 Comment
PayrollGeek 33.88 6/11/2019 Outperform 3Y $9.21 +122.80% +50.90% +71.90 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. mistermiranga 99.86 6/10/2019 Outperform 5Y $9.33 +119.94% +51.41% +68.52 0 Comment
bthym 55.53 4/16/2020 Outperform 5Y $10.77 +90.53% +57.10% +33.43 0 Comment
BigCaps18 30.94 7/13/2020 Underperform 5Y $18.50 +10.92% +36.98% +26.06 0 Comment
boomtracker 56.44 5/14/2020 Outperform 5Y $11.85 +73.16% +57.95% +15.22 0 Comment
jasonpicksstocks 65.97 1/14/2020 Outperform 1Y $13.79 +48.80% +33.68% +15.12 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. efarev 45.90 7/25/2017 Outperform 5Y $10.81 +89.80% +77.06% +12.74 0 Comment
ebadger33 < 20 5/8/2020 Outperform 3M $12.88 +59.32% +50.61% +8.70 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MYOV.